At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial to Investigate the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab and Rituximab for Waldenstrom Macroglobulinemia. Completed, enrolled 17 participants across 9 sites.
Detailed Summary
This study is for patients who have previously been treated for Waldenström's macroglobulinaemia (WM) and their disease has either not responded (known as refractory disease) or has returned (known as relapsed disease). Through this study, the researchers would like to find out whether treating these patients with drugs called rituximab and pembrolizumab is a safe and effective combination for this disease. In this study, pembrolizumab and rituximab will be given together. In other studies pembrolizumab has been shown to be effective at treating diseases similar to WM. The researchers want to test whether giving pembrolizumab and rituximab together is safe and effective.
Study Details
Timeline
Interventions
200 mg IV dose given on day 1 of a three week cycle
375 mg/m2 IV dose given up to 8 times in the trial